Lv1
20 积分 2023-08-04 加入
Systematic review of time to subsequent therapy as a candidate surrogate endpoint in advanced solid tumors
13小时前
待确认
Mass Balance, Metabolic Pathways, Absolute Bioavailability, and Pharmacokinetics of Giredestrant in Healthy Subjects
3天前
已完结
Overall Survival With First-Line vs Second-Line CDK4/6 Inhibitor Use in Advanced Breast Cancer
6天前
已完结
Rise and Fall of Neoadjuvant Carboplatin for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
27天前
已完结
First-Line Camizestrant for Emerging ESR1 -Mutated Advanced Breast Cancer
1个月前
已完结
Overall Survival with Inavolisib in PIK3CA -Mutated Advanced Breast Cancer
1个月前
已完结
Resistance mechanisms and therapeutic strategies of CDK4 and CDK6 kinase targeting in cancer
1个月前
已完结
MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II–III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study
1个月前
已完结
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial
2个月前
已完结
Treatment advances across the cervical cancer spectrum
2个月前
已完结
皖公网安备34019202002308
